TLDR Johnson & Johnson gains momentum after FDA approves Imaavy for rare blood disorder. JNJ expands cancer care reach after Europe approves Tecvayli combination treatment. New approvals stre
Johnson & Johnson (JNJ) gained attention after regulatory approvals expanded its healthcare portfolio across rare diseases and cancer treatments. The company secured U.S. FDA approval for Imaavy in warm autoimmune hemolytic anemia treatment. Meanwhile, European regulators approved expanded use of Tecvayli with daratumumab for multiple myeloma patients.Johnson & Johnson shares traded at $273.44, gaining 0.64% after recovering from early market volatility.
Johnson & Johnson received approval from the U.S. Food and Drug Administration for Imaavy’s expanded use. The treatment now covers patients aged 12 years and older with warm autoimmune hemolytic anemia. This approval applies to patients who currently receive or previously received steroid treatment.
Warm autoimmune hemolytic anemia is a rare condition where the immune system destroys red blood cells. Therefore, patients can experience severe anemia, fatigue, blood clots, and kidney complications. Johnson & Johnson developed Imaavy to reduce harmful antibodies while maintaining broader immune functions.
The treatment works by blocking a protein that supports antibody activity in the bloodstream. Additionally, Imaavy is delivered through intravenous infusion every four weeks based on patient weight. The approval followed a study involving 115 adults during mid-to-late stage clinical development.
The study showed stronger lasting improvements in hemoglobin levels among patients receiving Imaavy. After 24 weeks, more patients achieved sustained improvement compared with those receiving placebo treatment. However, reported side effects included swelling, diarrhea, fever, infections, and infusion-related reactions.
Johnson & Johnson also received approval from the European Commission for Tecvayli’s expanded application. The approval allows Tecvayli combined with daratumumab to treat adults with relapsed or refractory multiple myeloma. The treatment provides another option for patients after previous therapies fail.
Tecvayli is a bispecific antibody administered through a subcutaneous injection. It targets B-cell maturation antigen and CD3 to activate immune responses against cancer cells. Furthermore, combining Tecvayli with daratumumab creates a treatment approach that targets multiple disease pathways.
The European approval relied on results from the Phase III MajesTEC-3 study. The trial included patients who received one to three previous treatment lines. It compared the Tecvayli combination against established treatment options using daratumumab with other therapies.
The study reported improved progression-free survival and overall survival outcomes. The treatment combination reduced the risk of disease progression or death compared with standard therapies. Moreover, more than 90% of patients without progression at six months remained stable after three years.
Johnson & Johnson continues expanding its pharmaceutical business through new approvals and treatment developments. The company has focused on immunology, oncology, and rare disease medicines. These areas remain important parts of its healthcare growth strategy.
In January 2026, Johnson & Johnson reported fourth-quarter 2025 sales of $24.56 billion. The company recorded a 9.1% increase in sales compared with the previous period. Net earnings also increased 49.1% to $5.11 billion during the quarter.
The latest regulatory decisions strengthen Johnson & Johnson’s position in specialized healthcare markets. Imaavy expands the company’s immunology portfolio through rare disease treatment. Meanwhile, Tecvayli’s wider European use supports its presence in cancer care.
The post Johnson & Johnson (JNJ) Stock: Surge as FDA Approval and European Cancer Treatment Expansion Drive Market Attention appeared first on Blockonomi.
